CORESTEMCHEMON Inc. (KOSDAQ:166480)

South Korea flag South Korea · Delayed Price · Currency is KRW
2,700.00
-45.00 (-1.64%)
At close: Mar 12, 2026
Market Cap119.77B +39.7%
Revenue (ttm)20.13B -30.3%
Net Income-12.92B
EPS-491.98
Shares Out44.36M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume360,756
Average Volume775,253
Open2,745.00
Previous Close2,745.00
Day's Range2,620.00 - 2,815.00
52-Week Range1,014.00 - 4,310.00
Beta1.18
RSI45.49
Earnings DateMar 20, 2026

About CORESTEMCHEMON

CORESTEMCHEMON Inc., a bio-pharmaceutical company, engages in the development and production of stem cell therapies for the treatment of incurable diseases in South Korea. It offers NEURONATA-R inj, an autologous bone marrow mesenchymal stem cell therapy for the treatment of amyotrophic lateral sclerosis (ALS). The company also engages in the development of various therapy products for the treatment of systemic lupus erythematosus (SLE), multiple system atrophy (MSA), and cerebellar ataxia (CA) diseases. The company has a strategic partnership ... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2003
Employees 36
Stock Exchange KOSDAQ
Ticker Symbol 166480
Full Company Profile

Financial Performance

In 2024, CORESTEMCHEMON's revenue was 28.76 billion, a decrease of -14.54% compared to the previous year's 33.66 billion. Losses were -26.25 billion, 48.6% more than in 2023.

Financial Statements